PSMB9 and nasopharyngeal carcinoma: Another phase I trial (NCT03925896) is evaluating the safety and efficacy of LMP2-specific TCR T cells for HLA-A2, HLA-A11, and HLA-A24 recurrent and metastatic NPC patients.